Xenetic Biosciences (XBIO)
Market Price (6/24/2026): $2.95 | Market Cap: $6.8 MilSector: Health Care | Industry: Biotechnology
Xenetic Biosciences (XBIO)
Market Price (6/24/2026): $2.95Market Cap: $6.8 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -111% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -76% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -75% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -57%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% High stock price volatilityVol 12M is 169% Key risksXBIO key risks include [1] a persistent inability to secure funding or achieve profitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -111% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -64%, 3Y Excs Rtn is -76% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -2.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -75% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -57%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -57% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -38% |
| High stock price volatilityVol 12M is 169% |
| Key risksXBIO key risks include [1] a persistent inability to secure funding or achieve profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/22/2026
Xenetic Biosciences (XBIO) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Improved Fiscal Q1 2026 Financial Performance: Xenetic Biosciences reported a significant narrowing of its net loss by approximately 49% to $0.5 million for fiscal Q1 2026 (ended March 31, 2026), compared to the same period in 2025. Additionally, royalty revenue increased by approximately 36% year-over-year, reaching approximately $0.8 million. The company concluded the quarter with approximately $7.3 million in cash.
2. Presentation of Positive Preclinical Data at ASCO 2026: On June 1, 2026, Xenetic Biosciences showcased compelling preclinical data at the 2026 ASCO Annual Meeting. The data demonstrated that its DNase I significantly enhances CAR-T cell persistence, tumor control, and survival in aggressive hematologic cancer models, positioning it as a potentially transformative adjunct therapy for CAR-T treatment in B cell malignancies.
Show more
Xenetic Biosciences (XBIO) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Improved Fiscal Q1 2026 Financial Performance: Xenetic Biosciences reported a significant narrowing of its net loss by approximately 49% to $0.5 million for fiscal Q1 2026 (ended March 31, 2026), compared to the same period in 2025. Additionally, royalty revenue increased by approximately 36% year-over-year, reaching approximately $0.8 million. The company concluded the quarter with approximately $7.3 million in cash.
2. Presentation of Positive Preclinical Data at ASCO 2026: On June 1, 2026, Xenetic Biosciences showcased compelling preclinical data at the 2026 ASCO Annual Meeting. The data demonstrated that its DNase I significantly enhances CAR-T cell persistence, tumor control, and survival in aggressive hematologic cancer models, positioning it as a potentially transformative adjunct therapy for CAR-T treatment in B cell malignancies.
Show more
Updated on 6/22/2026
Xenetic Biosciences (XBIO) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Improved Fiscal Q1 2026 Financial Performance: Xenetic Biosciences reported a significant narrowing of its net loss by approximately 49% to $0.5 million for fiscal Q1 2026 (ended March 31, 2026), compared to the same period in 2025. Additionally, royalty revenue increased by approximately 36% year-over-year, reaching approximately $0.8 million. The company concluded the quarter with approximately $7.3 million in cash.
2. Presentation of Positive Preclinical Data at ASCO 2026: On June 1, 2026, Xenetic Biosciences showcased compelling preclinical data at the 2026 ASCO Annual Meeting. The data demonstrated that its DNase I significantly enhances CAR-T cell persistence, tumor control, and survival in aggressive hematologic cancer models, positioning it as a potentially transformative adjunct therapy for CAR-T treatment in B cell malignancies.
3. Approval for Exploratory Clinical Study of DNase I in Lymphoma: On June 4, 2026, Xenetic's collaboration partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will evaluate the combination of systemic DNase I with anti-CD19 CAR T cells in 12 patients with large B-cell lymphoma, building on strong positive preclinical results that showed enhanced anti-tumor activity.
Show less
Xenetic Biosciences (XBIO) stock has gained about 15% since 2/28/2026 because of the following key factors:
1. Improved Fiscal Q1 2026 Financial Performance: Xenetic Biosciences reported a significant narrowing of its net loss by approximately 49% to $0.5 million for fiscal Q1 2026 (ended March 31, 2026), compared to the same period in 2025. Additionally, royalty revenue increased by approximately 36% year-over-year, reaching approximately $0.8 million. The company concluded the quarter with approximately $7.3 million in cash.
2. Presentation of Positive Preclinical Data at ASCO 2026: On June 1, 2026, Xenetic Biosciences showcased compelling preclinical data at the 2026 ASCO Annual Meeting. The data demonstrated that its DNase I significantly enhances CAR-T cell persistence, tumor control, and survival in aggressive hematologic cancer models, positioning it as a potentially transformative adjunct therapy for CAR-T treatment in B cell malignancies.
3. Approval for Exploratory Clinical Study of DNase I in Lymphoma: On June 4, 2026, Xenetic's collaboration partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will evaluate the combination of systemic DNase I with anti-CD19 CAR T cells in 12 patients with large B-cell lymphoma, building on strong positive preclinical results that showed enhanced anti-tumor activity.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 14.6% change in XBIO stock from 2/28/2026 to 6/23/2026 was primarily driven by a 52.6% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.53 | 2.90 | 14.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 11.6% |
| P/S Multiple | 1.4 | 2.1 | 52.6% |
| Shares Outstanding (Mil) | 2 | 2 | -32.7% |
| Cumulative Contribution | 14.6% |
Market Drivers
2/28/2026 to 6/23/2026| Return | Correlation | |
|---|---|---|
| XBIO | 14.6% | |
| Market (SPY) | 7.2% | 26.1% |
| Sector (XLV) | -4.6% | 14.5% |
Fundamental Drivers
The 10.3% change in XBIO stock from 11/30/2025 to 6/23/2026 was primarily driven by a 46.8% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.63 | 2.90 | 10.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 11.6% |
| P/S Multiple | 1.4 | 2.1 | 46.8% |
| Shares Outstanding (Mil) | 2 | 2 | -32.7% |
| Cumulative Contribution | 10.3% |
Market Drivers
11/30/2025 to 6/23/2026| Return | Correlation | |
|---|---|---|
| XBIO | 10.3% | |
| Market (SPY) | 8.0% | 18.8% |
| Sector (XLV) | -2.7% | 8.1% |
Fundamental Drivers
The -3.3% change in XBIO stock from 5/31/2025 to 6/23/2026 was primarily driven by a -32.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.00 | 2.90 | -3.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 3 | 23.5% |
| P/S Multiple | 1.8 | 2.1 | 16.3% |
| Shares Outstanding (Mil) | 2 | 2 | -32.7% |
| Cumulative Contribution | -3.3% |
Market Drivers
5/31/2025 to 6/23/2026| Return | Correlation | |
|---|---|---|
| XBIO | -3.3% | |
| Market (SPY) | 25.9% | 14.7% |
| Sector (XLV) | 16.8% | 6.9% |
Fundamental Drivers
The -2.8% change in XBIO stock from 5/31/2023 to 6/23/2026 was primarily driven by a -33.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6232026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.98 | 2.90 | -2.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 3 | 65.8% |
| P/S Multiple | 2.4 | 2.1 | -11.5% |
| Shares Outstanding (Mil) | 2 | 2 | -33.8% |
| Cumulative Contribution | -2.8% |
Market Drivers
5/31/2023 to 6/23/2026| Return | Correlation | |
|---|---|---|
| XBIO | -2.8% | |
| Market (SPY) | 82.4% | 12.0% |
| Sector (XLV) | 25.1% | 8.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XBIO Return | -37% | -78% | 21% | 16% | -46% | 35% | -86% |
| Peers Return | -23% | -26% | 1% | -9% | -6% | 22% | -40% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| XBIO Win Rate | 33% | 33% | 67% | 58% | 50% | 83% | |
| Peers Win Rate | 45% | 42% | 35% | 50% | 50% | 43% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| XBIO Max Drawdown | -76% | -80% | -64% | -33% | -81% | -25% | |
| Peers Max Drawdown | -47% | -45% | -45% | -47% | -47% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GILD, BMY, CRSP, ALLO, IOVA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/23/2026 (YTD)
How Low Can It Go
| Event | XBIO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.0% | -18.8% |
| % Gain to Breakeven | 78.7% | 23.1% |
| Time to Breakeven | 89 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -19.8% | -7.8% |
| % Gain to Breakeven | 24.8% | 8.5% |
| Time to Breakeven | 5 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -30.5% | -9.5% |
| % Gain to Breakeven | 43.8% | 10.5% |
| Time to Breakeven | 23 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -53.8% | -6.7% |
| % Gain to Breakeven | 116.5% | 7.1% |
| Time to Breakeven | 126 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.8% | -33.7% |
| % Gain to Breakeven | 155.1% | 50.9% |
| Time to Breakeven | 83 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -41.0% | -3.7% |
| % Gain to Breakeven | 69.4% | 3.9% |
| Time to Breakeven | 368 days | 6 days |
In The Past
Xenetic Biosciences's stock fell -44.0% during the 2025 US Tariff Shock. Such a loss loss requires a 78.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | XBIO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.0% | -18.8% |
| % Gain to Breakeven | 78.7% | 23.1% |
| Time to Breakeven | 89 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -30.5% | -9.5% |
| % Gain to Breakeven | 43.8% | 10.5% |
| Time to Breakeven | 23 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -53.8% | -6.7% |
| % Gain to Breakeven | 116.5% | 7.1% |
| Time to Breakeven | 126 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.8% | -33.7% |
| % Gain to Breakeven | 155.1% | 50.9% |
| Time to Breakeven | 83 days | 140 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -41.0% | -3.7% |
| % Gain to Breakeven | 69.4% | 3.9% |
| Time to Breakeven | 368 days | 6 days |
In The Past
Xenetic Biosciences's stock fell -44.0% during the 2025 US Tariff Shock. Such a loss loss requires a 78.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Xenetic Biosciences (XBIO)
Xenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on the discovery, research, and development of advanced biologic drugs and oncology therapeutics. The company aims to innovate cancer treatments and enhance drug delivery systems, positioning itself at the forefront of personalized medicine and pharmaceutical collaboration.
The company's core technology is XCART, a personalized chimeric antigen receptor T cell (CAR T) platform. This platform is engineered to target patient-specific tumor neoantigens, with an initial focus on developing cell-based therapeutics for B-cell lymphomas. By targeting the B-cell receptor on an individual patient's malignant tumor cells, XCART seeks to provide highly individualized and effective treatments for these challenging cancers.
Additionally, Xenetic leverages its proprietary drug delivery platform, PolyXen, through strategic partnerships. Rather than developing its own drugs with PolyXen, the company collaborates with other biotechnology and pharmaceutical companies, allowing them to utilize PolyXen to improve their drug candidates. Therefore, Xenetic's primary markets include patients suffering from B-cell lymphomas, and the broader pharmaceutical industry through its PolyXen collaborations with partners like Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited.
AI Analysis | Feedback
Here are 1-2 brief analogies for Xenetic Biosciences (XBIO):
- Like a highly specialized, personalized version of a CAR T-cell therapy company such as Novartis or Gilead, focusing on tailoring cancer treatments to individual patient tumors.
- A biotech platform company, akin to Alkermes, that develops and licenses out its drug delivery technology to other pharmaceutical partners.
AI Analysis | Feedback
- XCART: A personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens for B-cell lymphomas.
- PolyXen: A proprietary drug delivery platform that the company leverages through partnerships with biotechnology and pharmaceutical companies.
AI Analysis | Feedback
Xenetic Biosciences (XBIO) primarily sells its technology and services to other biotechnology and pharmaceutical companies through collaboration agreements and partnerships. Its major customers/partners identified in the provided description include:
- Takeda Pharmaceutical Co. Ltd. (NYSE: TAK)
- Serum Institute of India Limited
- PJSC Pharmsynthez (MOEX: PHST)
- SynBio LLC
AI Analysis | Feedback
null
AI Analysis | Feedback
James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
Mr. Parslow is a seasoned executive with over 35 years of experience providing financial and business leadership to the biotech, clean tech, e-commerce, and high-tech manufacturing industries. Prior to joining Xenetic, Mr. Parslow served as Chief Financial Officer, Treasurer, and Secretary of World Energy Solutions, Inc., a publicly-traded business-to-business e-commerce company. During his tenure there, he oversaw the company's growth from a $5 million private company with 15 employees to a $40 million public company with 135 employees and led an IPO that raised $31 million in total proceeds. He also led finance teams at both large and small public companies, including Thermo Fisher. Mr. Parslow previously served as Interim CFO at Industrial Physics, LLC and Big Belly Solar. He has served as Xenetic's Chief Financial Officer since April 2017.
Scott N. Cullison, Executive Consultant for Business Development
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry to Xenetic. His expertise spans business development, alliance management, commercialization, product management, R&D program team leadership, and strategic planning. He has successfully secured multiple transformative deals with major pharmaceutical companies. Mr. Cullison currently serves as the Owner/Consultant for Stride BDCOM Consulting, where he provides senior executive level business development and commercial planning strategy/execution services to the biotech/pharma industry.
Reid P. Bissonnette, Ph.D., Executive Consultant for Translational Research and Development
Dr. Bissonnette has over 25 years of experience in small molecule drug discovery and development and biotherapeutics. He is recognized as a translational scientist, drug hunter, and senior manager of Oncology and Inflammation drug research and development, particularly in targeted therapeutics, oncology, immuno-oncology, and inflammation therapeutics.
AI Analysis | Feedback
```html
```
Key Business Risks for Xenetic Biosciences (XBIO)
- Financial Position and Funding Requirements: Xenetic Biosciences has a history of operating losses and an accumulated deficit, indicating it has not yet achieved profitability. The company anticipates incurring significant additional operating losses as it expands its research, development, and commercialization efforts. Consequently, Xenetic will require substantial additional capital to fund its operations and achieve its strategic objectives, particularly for the research and development and regulatory approval of its drug candidates. Failure to obtain the necessary funding on acceptable terms, or at all, could force the company to delay, limit, or terminate product development, other operations, or commercialization efforts, posing a risk to its ability to continue as a going concern. Raising additional capital may also lead to significant dilution for existing shareholders.
- Regulatory and Commercialization Risks: As a biopharmaceutical company, Xenetic Biosciences operates in a highly regulated environment. A key risk involves the inherent uncertainties and challenges associated with successfully completing preclinical and clinical studies, obtaining the necessary regulatory approvals for its drug candidates (such as the XCART platform and the DNase platform), and achieving commercial success in the competitive biopharmaceutical market. There is no guarantee that any current or future drug candidate will successfully navigate these processes, or that, even if approved, it will be commercially viable.
- Uncertainty of Strategic Review Outcomes: Xenetic Biosciences has initiated a formal strategic review process to explore various alternatives to maximize shareholder value, including a potential sale of the company or its assets, or business combinations. The outcome and timing of this strategic review are uncertain, and there is no assurance that any proposal will be made, accepted, or consummated. The announcement or a failure to consummate a transaction could disrupt the company's business operations and negatively impact its stock price.
AI Analysis | Feedback
The rapid development and potential commercialization of allogeneic ("off-the-shelf") CAR T cell therapies and other next-generation CAR T platforms (e.g., in vivo CAR T, universal CARs) pose a clear emerging threat. These technologies aim to overcome the manufacturing complexity, high cost, and extended vein-to-vein time associated with existing personalized, autologous CAR T cell therapies like Xenetic Biosciences' XCART. If successful, these more accessible and potentially more cost-effective CAR T approaches could significantly disrupt the market for personalized CAR T cell therapies, making them less competitive.
AI Analysis | Feedback
Xenetic Biosciences (XBIO) focuses on two main product areas: XCART, a personalized CAR T platform targeting B-cell lymphomas, and PolyXen, a proprietary drug delivery platform.
XCART Platform (Personalized CAR T for B-cell Lymphomas)
The addressable market for Xenetic Biosciences' XCART platform can be considered within the broader CAR T-cell therapy market and the B-cell lymphoma treatment market, with a specific focus on personalized cell therapies.
- The global CAR T-cell therapy market was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, with a compound annual growth rate (CAGR) of 18.06% from 2026 to 2033. The lymphoma segment accounted for the largest revenue share in the CAR T-cell therapy market in 2025, holding 52.86%, and is expected to be the fastest-growing segment, driven by the high prevalence of B-cell lymphomas. Other estimates for the global CAR T-cell therapy market predict a rise from USD 20.54 billion in 2025 to approximately USD 268.0 billion by 2035, growing at a CAGR of 29.29%.
- The global B-cell lymphoma treatment market was valued at USD 4.1 billion in 2024 and is projected to grow to USD 6.9 billion by 2033, exhibiting a CAGR of 8.4% from 2025 to 2033. Another report estimates the global B-cell lymphoma market size at USD 5.08 billion in 2024, projected to reach USD 10 billion by 2034 with a CAGR of 7.00% from 2025 to 2034. For the 7 Major Markets (7MM), the B-cell Lymphoma market reached USD 4.9 billion in 2024 and is expected to reach USD 8.9 billion by 2035, at a CAGR of 5.79% during 2025-2035.
- The global personalized cell therapy market, which encompasses technologies like XCART, is expected to expand from USD 37.29 billion in 2025 to USD 235.65 billion by 2034, demonstrating a robust CAGR of 22.81%. North America led the personalized cell therapy market in 2024.
PolyXen Platform (Drug Delivery)
The addressable market for Xenetic Biosciences' PolyXen drug delivery platform can be assessed by the overall drug delivery market and the biologics market, as PolyXen is leveraged for partnering with biotechnology and pharmaceutical companies for biologic drugs and oncology therapeutics.
- The global pharmaceutical drug delivery market was valued at USD 1,465.2 billion in 2024 and is estimated to reach USD 2,205.5 billion by 2033, growing at a CAGR of 4.6% during 2025-2033. North America held the largest market share in 2024, accounting for 42.6%. Alternatively, the global drug delivery devices market size was estimated at USD 410.61 billion in 2024 and is expected to reach USD 862.16 billion by 2034, growing at a CAGR of 7.7% from 2025 to 2034.
- The global biologics market was calculated at USD 487 billion in 2025 and is predicted to increase to approximately USD 1243.80 billion by 2035, expanding at a CAGR of 9.83% from 2026 to 2035. Another source indicates the global market for biologic therapeutic drugs is estimated to increase from USD 499.2 billion in 2024 to reach USD 794.5 billion by 2029, at a CAGR of 9.7% from 2024 through 2029. North America is expected to be the dominant region in the biologics market, projected to hold 36.7% of the market share in 2025.
- Within the pharmaceutical drug delivery market, oncology applications account for approximately 20.2% of the market share. Similarly, oncology leads the drug delivery devices market by application, with 29.2% of the market share.
AI Analysis | Feedback
Xenetic Biosciences, Inc. (XBIO) is expected to drive future revenue growth over the next 2-3 years through several key areas:
- Increased Royalty Revenue from PolyXen Platform: Xenetic Biosciences anticipates continued growth in royalty payments from its proprietary PolyXen drug delivery platform. Royalty revenue from a sublicense agreement with Takeda Pharmaceutical Co. Ltd., for example, increased by 19% year-over-year to $3.0 million in 2025. This platform aims to improve the pharmacokinetic profiles and extend the active life of biologic drugs, and further commercialization of products utilizing PolyXen by partners is expected to contribute to revenue.
- Advancement and Potential Commercialization of XCART: The XCART personalized chimeric antigen receptor T cell (CAR T) platform technology represents a significant future revenue driver. Xenetic is actively engaged in preclinical development of XCART, a differentiated approach to CAR T therapy for B-cell lymphomas. Collaborations with institutions like Scripps Research and Pharmsynthez are designed to advance the technology toward Investigational New Drug (IND)-enabling studies and potentially into Phase 1 clinical trials, with a potential global market opportunity for B-cell Non-Hodgkin lymphoma alone estimated to be over $7 billion annually.
- Development and Potential Commercialization of DNase-based Immuno-oncology Programs: The company is focused on advancing its DNase-based immuno-oncology programs for difficult-to-treat solid cancers. Xenetic is moving its DNase-based technology towards Phase 1 clinical development for indications such as pancreatic carcinoma and other locally advanced or metastatic solid tumors. Collaborations, including one with PeriNess Ltd. for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma, and ongoing investigator-initiated trials, could lead to future product revenue.
- New Strategic Collaborations and Partnerships: Xenetic Biosciences actively pursues strategic collaborations and partnerships to leverage its proprietary technologies. The company is open to partnerships for its PolyXen platform and its DNase oncology platform. New agreements or expansion of existing collaborations could provide non-dilutive funding through upfront payments and milestones, and establish future royalty streams as partnered products advance through development and potential commercialization.
AI Analysis | Feedback
Share Issuance
- Xenetic Biosciences completed an underwritten public offering in October 2025, which secured net proceeds of approximately $3.9 million. The offering involved 735,000 shares of common stock at a public price of $6.12 per share, generating gross proceeds of approximately $4.5 million.
- The company utilized a shelf registration statement on Form S-3, declared effective on November 1, 2024, for its offerings.
- Additional paid-in capital increased by approximately $50,789 from December 31, 2024, to September 30, 2025.
Inbound Investments
- Royalty revenue from the sublicense agreement with Takeda Pharmaceuticals Co. Ltd. increased approximately 19% to $3.0 million for the year ended December 31, 2025, up from $2.5 million in the prior year.
- Xenetic entered into a Clinical Trial Services Agreement with PeriNess Ltd. in December 2024, under which PeriNess will manage regulatory approval and operational execution for exploratory investigator-initiated studies of recombinant DNase.
- The company extended its collaboration with Scripps Research for its DNase platform.
Capital Expenditures
- Research and development expenses for the year ended December 31, 2025, decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in 2024.
- Increased manufacturing development efforts and pre-clinical research were primary factors contributing to increased research & development expenses in the third quarter of 2025.
- The company's primary focus for capital allocation involves advancing its DNase-based technology towards Phase 1 clinical development for treating pancreatic carcinoma and other solid tumors.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 29.21 |
| Mkt Cap | 3.5 |
| Rev LTM | 144 |
| Op Inc LTM | -95 |
| FCF LTM | -56 |
| FCF 3Y Avg | -91 |
| CFO LTM | -56 |
| CFO 3Y Avg | -90 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.5% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 20.2% |
| QoQ Delta Rev Chg LTM | 4.1% |
| Op Inc Chg LTM | 18.0% |
| Op Inc Chg 3Y Avg | 11.6% |
| Op Mgn LTM | -75.1% |
| Op Mgn 3Y Avg | -141.5% |
| QoQ Delta Op Mgn LTM | 10.2% |
| CFO/Rev LTM | -57.1% |
| CFO/Rev 3Y Avg | -110.2% |
| FCF/Rev LTM | -57.1% |
| FCF/Rev 3Y Avg | -110.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Pre-clinical research and development activities | 3 | 3 | 3 | 2 | 1 |
| Total | 3 | 3 | 3 | 2 | 1 |
| $ Mil | 2025 | 2024 |
|---|---|---|
| Pre-clinical research and development activities | -3 | -4 |
| Total | -3 | -4 |
| $ Mil | 2018 |
|---|---|
| Pre-clinical research and development activities | 14 |
| Total | 14 |
Price Behavior
Price Behavior
| Market Price | $2.90 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 05/23/2014 | |
| Distance from 52W High | -72.0% | |
| 50 Days | 200 Days | |
| DMA Price | $3.11 | $2.95 |
| DMA Trend | indeterminate | up |
| Distance from DMA | -6.8% | -1.8% |
| 3M | 1YR | |
| Volatility | 57.9% | 169.4% |
| Downside Capture | 333.60 | 235.75 |
| Upside Capture | 191.43 | 185.20 |
| Correlation (SPY) | 37.6% | 15.0% |
XBIO Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.58 | 0.92 | 1.04 | 0.82 | 1.99 | 0.86 |
| Up Beta | -1.49 | -2.51 | -0.95 | -0.26 | -0.18 | 0.32 |
| Down Beta | -0.12 | -0.30 | 0.46 | -1.15 | 2.86 | 1.18 |
| Up Capture | 212% | 258% | 246% | 240% | 285% | 64% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 9 | 21 | 30 | 59 | 111 | 349 |
| Down Capture | 417% | 550% | 188% | 173% | 176% | 103% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 10 | 19 | 30 | 57 | 129 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XBIO | |
|---|---|---|---|---|
| XBIO | 12.7% | 169.2% | 0.61 | - |
| Sector ETF (XLV) | 16.9% | 15.1% | 0.83 | 6.4% |
| Equity (SPY) | 24.6% | 12.5% | 1.48 | 14.7% |
| Gold (GLD) | 21.8% | 27.6% | 0.70 | 9.7% |
| Commodities (DBC) | 16.7% | 18.8% | 0.69 | 3.0% |
| Real Estate (VNQ) | 12.3% | 13.8% | 0.60 | -3.4% |
| Bitcoin (BTCUSD) | -38.0% | 42.5% | -1.01 | 15.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XBIO | |
|---|---|---|---|---|
| XBIO | -33.5% | 108.1% | 0.02 | - |
| Sector ETF (XLV) | 5.8% | 14.8% | 0.21 | 9.6% |
| Equity (SPY) | 13.1% | 17.1% | 0.59 | 14.0% |
| Gold (GLD) | 16.8% | 18.3% | 0.74 | 8.5% |
| Commodities (DBC) | 7.3% | 19.4% | 0.28 | 6.2% |
| Real Estate (VNQ) | 2.4% | 18.9% | 0.03 | 8.6% |
| Bitcoin (BTCUSD) | 9.7% | 54.1% | 0.38 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with XBIO | |
|---|---|---|---|---|
| XBIO | -40.2% | 136.1% | 0.11 | - |
| Sector ETF (XLV) | 9.8% | 16.6% | 0.48 | 8.1% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 10.0% |
| Gold (GLD) | 11.9% | 16.1% | 0.61 | 2.1% |
| Commodities (DBC) | 5.9% | 18.0% | 0.25 | 6.1% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 8.1% |
| Bitcoin (BTCUSD) | 57.0% | 66.5% | 0.97 | 5.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/13/2026 | 9.5% | 18.1% | 21.2% |
| 11/13/2025 | -2.7% | -3.8% | -11.7% |
| 8/13/2025 | 7.2% | 1.0% | 11.1% |
| 5/14/2025 | 2.0% | -0.7% | 5.9% |
| 3/19/2025 | 1.8% | -2.3% | -30.3% |
| 11/13/2024 | -11.6% | -5.6% | 1.7% |
| 8/14/2024 | -6.0% | 16.3% | 9.9% |
| 5/10/2024 | -3.6% | -12.2% | -3.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 11 |
| # Negative | 9 | 11 | 11 |
| Median Positive | 2.8% | 5.8% | 11.1% |
| Median Negative | -3.6% | -5.6% | -17.4% |
| Max Positive | 9.5% | 18.1% | 142.2% |
| Max Negative | -17.5% | -33.5% | -31.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/13/2026 | 9.5% | 18.1% | 21.2% |
| 11/13/2025 | -2.7% | -3.8% | -11.7% |
| 8/13/2025 | 7.2% | 1.0% | 11.1% |
| 5/14/2025 | 2.0% | -0.7% | 5.9% |
| 3/19/2025 | 1.8% | -2.3% | -30.3% |
| 11/13/2024 | -11.6% | -5.6% | 1.7% |
| 8/14/2024 | -6.0% | 16.3% | 9.9% |
| 5/10/2024 | -3.6% | -12.2% | -3.5% |
| 3/22/2024 | -2.3% | -4.6% | -4.8% |
| 11/13/2023 | -0.3% | 10.0% | 25.8% |
| 8/11/2023 | 0.8% | 5.8% | 28.3% |
| 5/11/2023 | -17.5% | -33.5% | -20.7% |
| 3/23/2023 | 0.0% | 6.9% | 8.3% |
| 11/10/2022 | 4.3% | 12.8% | 6.4% |
| 8/12/2022 | 4.8% | -6.9% | -17.4% |
| 3/23/2022 | 4.8% | 1.0% | -5.2% |
| 11/12/2021 | 1.8% | -15.0% | -13.8% |
| 8/13/2021 | -5.5% | -12.1% | -31.0% |
| 5/12/2021 | -2.2% | 5.0% | 26.0% |
| 3/17/2021 | 2.8% | -0.4% | -22.3% |
| 11/13/2020 | 2.9% | 3.8% | 142.2% |
| 8/13/2020 | 0.8% | 0.0% | -27.5% |
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 11 |
| # Negative | 9 | 11 | 11 |
| Median Positive | 2.8% | 5.8% | 11.1% |
| Median Negative | -3.6% | -5.6% | -17.4% |
| Max Positive | 9.5% | 18.1% | 142.2% |
| Max Negative | -17.5% | -33.5% | -31.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/22/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/12/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/22/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/22/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/11/2021 | 10-Q |
| 12/31/2020 | 03/16/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/12/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 03/26/2020 | 10-K |
| 09/30/2019 | 11/14/2019 | 10-Q |
| 06/30/2019 | 08/14/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/23/2026